X

Trial Profile

Phase II/III Randomized, Controlled Clinical Study of AlloStim(R) vs Physician's Choice in Asian Subjects With Advanced Hepatocellular Carcinoma

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 18 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs T-cell vaccine-AlloStim (Primary) ; T-cell vaccine-AlloStim (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
Indications Liver cancer
Focus Therapeutic Use
Acronyms ALIVE
Sponsors Immunovative Therapies

Most Recent Events

04 Mar 2024 Planned primary completion date changed from 1 Jun 2025 to 1 Aug 2025.
04 Mar 2024 Status changed from not yet recruiting to recruiting.
28 Feb 2023 Planned End Date changed from 1 Feb 2025 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com